Charles River wins gene therapy manufacturing contract from Nanoscope
Charles River Laboratories’ growing gene therapy manufacturing capabilities have landed it a deal with the eye disease biotech Nanoscope Therapeutics.
Charles River Laboratories’ growing gene therapy manufacturing capabilities have landed it a deal with the eye disease biotech Nanoscope Therapeutics.
Japanese CDMO expands services to meet demand for parenteral drugs for global customers.
A $114m diversity in clinical trials initiative supported by the Bristol Myers Squibb Foundation (BMSF) and Gilead Sciences has selected 64 physicians for awards.
The facility will comprise of a standalone building to consolidate repackaging and distribution operations in the state of New York, US.